NEXLIZET is a combination of 2 medicines, bempedoic acid and ezetimibe. The bempedoic acid portion of NEXLIZET was studied in a large clinical trial on reducing heart attack and heart procedures, like …

26 sep. 2024 · Nexlizet (bempedoic acid and ezetimibe) may be used to reduce LDL-C levels in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), alone or in …

4 apr. 2025 · Nexlizet (bempedoic acid/ezetimibe) is a prescription tablet used to reduce low-density lipoprotein (LDL) cholesterol in certain people. Learn about dosage, side effects, and more.

30 jun. 2024 · What is Nexlizet used for? Nexlizet (bempedoic acid/ ezetimibe) is commonly used for the following conditions. To lower the risk of heart attack and certain heart procedures like stent …

27 mei 2025 · Nexlizet (bempedoic acid/ezetimibe) is a prescription tablet used to help lower cholesterol and reduce the risk of heart attack as well as heart surgery. Nexlizet is prescribed for …

The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than placebo were …

Bempedoic acid, a component of NEXLIZET, is used: to lower the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, or heart procedures like …

Nexlizet is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular …

INDICATION NEXLIZET is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic …

ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions …